EASD24: Novo Nordisk’s Saxenda and Its Impact on Pediatric Weight Loss
Wednesday, 11 September 2024, 03:52
EASD24 Conference Highlights
The recent EASD24 conference revealed compelling data regarding Saxenda, a medication developed by Novo Nordisk, which is showing effectiveness in promoting weight loss in children. This session emphasized the growing need for effective strategies to combat the rising rates of obesity among pediatric populations.
Clinical Trial Results
- Participants experienced notable reductions in body weight.
- Long-term efficacy was demonstrated with minimal side effects.
The findings suggest that Saxenda can be a part of comprehensive weight management plans for children.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.